These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. Tavridou A; Manolopoulos VG Eur J Pharmacol; 2004 Nov; 505(1-3):213-21. PubMed ID: 15556155 [TBL] [Abstract][Full Text] [Related]
7. Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents. Kourounakis AP; Katselou MG; Matralis AN; Ladopoulou EM; Bavavea E Curr Med Chem; 2011; 18(29):4418-39. PubMed ID: 21864285 [TBL] [Abstract][Full Text] [Related]
8. Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity. Katselou MG; Matralis AN; Kourounakis AP Eur J Med Chem; 2017 Sep; 138():748-760. PubMed ID: 28728107 [TBL] [Abstract][Full Text] [Related]
12. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728 [TBL] [Abstract][Full Text] [Related]
13. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Shiomi M; Yamada S; Amano Y; Nishimoto T; Ito T Br J Pharmacol; 2008 Jul; 154(5):949-57. PubMed ID: 18587443 [TBL] [Abstract][Full Text] [Related]
14. Thiomorpholine Derivatives with Hypolipidemic and Antioxidant Activity. Tooulia KK; Theodosis-Nobelos P; Rekka EA Arch Pharm (Weinheim); 2015 Sep; 348(9):629-34. PubMed ID: 26191791 [TBL] [Abstract][Full Text] [Related]
15. Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity. Matralis AN; Kourounakis AP J Med Chem; 2014 Mar; 57(6):2568-81. PubMed ID: 24568631 [TBL] [Abstract][Full Text] [Related]
16. A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor. Kerr AG; Tam LCS; Hale AB; Cioroch M; Douglas G; Agkatsev S; Hibbitt O; Mason J; Holt-Martyn J; Bataille CJR; Wynne GM; Channon KM; Russell AJ; Wade-Martins R J Pharmacol Exp Ther; 2017 Jun; 361(3):417-428. PubMed ID: 28360334 [TBL] [Abstract][Full Text] [Related]
17. New lipid-lowering agents acting on LDL receptors. Scharnagl H; März W Curr Top Med Chem; 2005; 5(3):233-42. PubMed ID: 15857307 [TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Amano Y; Nishimoto T; Tozawa Ri; Ishikawa E; Imura Y; Sugiyama Y Eur J Pharmacol; 2003 Apr; 466(1-2):155-61. PubMed ID: 12679152 [TBL] [Abstract][Full Text] [Related]
19. Effect of a new squalene synthase inhibitor on an ApoE Matralis AN; Kaklamanis L; Perrea D; Kourounakis AP Bioorg Med Chem; 2023 Jul; 90():117378. PubMed ID: 37336084 [TBL] [Abstract][Full Text] [Related]
20. Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis. Matralis AN; Bavavea EI; Incerpi S; Pedersen JZ; Kourounakis AP Curr Med Chem; 2017; 24(12):1214-1227. PubMed ID: 27528055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]